Free-text search
Articles per year:
Content Types
-
They take the helm as Mölnlycke splits in two
Swedish medtech company Mölnlycke has appointed Anders Andersson as its new CEO and Fredrik Wallefors as head of its Surgical business area. The appointments come ahead of the planned split of the medtech company into two independent businesses.
-
Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”
BioArctic is losing out on potential milestone payments after Novartis decided to discontinue a research programme involving the Swedish company's BrainTransporter technology. Despite the setback, BioArctic says it is pleased with the preclinical data.
-
Five doctors charged in Swedish prescription fraud scheme
Thirteen people, including five doctors, have been charged in a multi-million-krona fraud scheme in which a drug used to treat excessive sweating is suspected of having been prescribed without medical justification.
-
Child dies as measles cases surge across US
A child in New York has died from measles, Reuters reports, marking the first known measles-related death in the state in more than three decades. The death comes as the US faces its sharpest rise in measles cases for many years.
-
Lytix reports positive cancer data – plans larger trial
Norwegian biotech company Lytix Biopharma has reported positive phase II results for its drug candidate ruxotemitide in melanoma. The company is now aiming for a randomised phase III trial.
-
AstraZeneca drops two early-stage prostate cancer drugs
Two of AstraZeneca’s experimental prostate cancer treatments have come to an early end. The pharmaceutical company is discontinuing development of candidates AZD9750 and AZD8359, just months after their first clinical trials began.
-
Major deal gives Fresenius access to 37 biosimilar candidates – “We are doubling down”
Fresenius and China's WuXi Biologics have signed an agreement that the German healthcare group describes as “the largest development agreement announced in the biosimilars industry to date”.
-
Atlas Antibodies replaces CEO – brings in former OssDsign chief
Swedish biotech Atlas Antibodies is replacing its CEO, Dan Pitulia. He is succeeded by interim CEO Morten Henneveld.
-
EU Biotech Act: Extended drug protection sparks debate
An extra year of protection for biotech medicines could boost investment in Europe – but also delay access to cheaper alternatives. The proposal is one of the most contentious elements of the EU's new Biotech Act.
-
Alligator Bioscience sells mitazalimab – potential to receive more than 1 billion
Biotechnology company Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil, according to a press release.
-
A Biotech CTO on the Outsourcing Dilemma: “The Stakes Are Extremely High”
For small biotech companies, external expertise can be essential to moving drug development forward. But what happens when priorities shift, financing changes and every milestone matters? Ahead of Pharma Outsourcing – Find the Right Partner in Stockholm on 2 December, we spoke with conference moderator Pernille Hemmingsen, CTO at Adcendo, about the challenges of working with external development partners.
-
Eli Lilly drops Alzheimer’s drug candidate after phase II trial
Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expectations – even as the pharmaceutical giant invests billions to strengthen its neurology portfolio.
-
AstraZeneca unveils major cost-cutting drive
AstraZeneca beat market expectations in the third quarter. At the same time, the company announced a cost-cutting programme expected to generate annual savings of 1.5 billion dollars.
-
Sobi proposes Börje Ekholm as new chair
Börje Ekholm, the former CEO of Ericsson, has been proposed as the new chair of Sobi.
-
SynAct Pharma signs first dengue drug deal
SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.
-
Lilly’s triple-G drug outperforms Ozempic in head-to-head trial
Eli Lilly’s investigational drug retatrutide delivered more than twice the weight loss of rival Novo Nordisk’s Ozempic in a head-to-head phase 3 trial.
-
Ferring to buy IVF biotech in billion-dollar deal
Ferring has signed an agreement to acquire US biotechnology company Gameto in a deal worth up to $1.4 billion.
-
Danish drug candidate shows great response to two cancer types
Genmab’s hopes for petosemtamab have been boosted by positive phase II results in two cancer indications. The bispecific antibody showed promising efficacy in combination with established treatments for colorectal and head and neck cancers.
-
Abbott sharpens cancer test – detects smaller traces of tumour DNA
A single tumour DNA molecule among more than a million others. That is how small a trace of cancer Abbott’s upgraded Oncodetect test is designed to detect in the blood. The technology has now also demonstrated improved performance in clinical studies.
-
Cell therapy scrapped after patient deaths in trial — 94 per cent of staff laid off
US biotech company Artiva Biotherapeutics is discontinuing the development of a cell therapy for autoimmune diseases and laying off 94 per cent of its workforce after two patients died during a clinical trial and the treatment’s effects proved less durable than expected.
-
Björn Ursing: “What happens when trust in science erodes?”
Medical breakthroughs have transformed healthcare, but scientific progress alone is not enough. As misinformation spreads and trust in science comes under pressure, how can we ensure that healthcare decisions remain grounded in evidence? Björn Ursing explores the question in this column.
-
AstraZeneca considers move into cancer vaccines
AstraZeneca is considering developing cancer vaccines based on mRNA technology, CEO Pascal Soriot said at a conference on Tuesday, Bloomberg News reports.
-
AlzeCure CEO steps down – co-founder takes over
Two multibillion-dollar deals, the company’s first profit and an oversubscribed share issue. After an eventful year, AlzeCure Pharma is changing CEO. Martin Jönsson is stepping down after almost seven years and will be temporarily replaced by Chief Scientific Officer and co-founder Johan Sandin.
-
Xbrane wins long-awaited FDA approval for eye drug biosimilar
After a long and winding road, Xbrane has now received FDA approval for Lucamzi, a biosimilar to the eye drug Lucentis.
BREAKING